Amerisource Bergen Corp.
ABC - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$63.35B
Close$
Earnings Call Q3 2026
August 5, 2026 - AI Summary
Strong Q3 performance; EPS up ~12% and business momentum
- Revenue: $84.8B (+5% YoY), supported by both segments and “Other.”
- Adjusted operating income: $1.2B (+17% YoY) (driven by strong execution in U.S. and International, plus contributions from OneOncology).
- Adjusted EPS: +12% YoY (also supported by share repurchases).
Guidance raised for FY2026 (key forecast change)
- FY2026 adjusted EPS guidance increased to $17.75–$17.95 (from $17.70–$17.90).
- Revenue guidance unchanged overall:
- U.S. Healthcare Solutions revenue: still 4%–6% growth, but company expects lower half of that range given current assumptions.
- International Healthcare Solutions revenue: raised—~8% growth at low end of prior range; ~7% constant currency.
- Other revenue: ~6% growth expected.
- Consolidated adjusted operating income growth: now 13%–14% (raised bottom end).
- Q4 commentary (implied): management indicated strong double-digit growth sequentially, with U.S. benefiting from easier expense comparisons and the lapped oncology customer loss.
Capital return/buybacks: $1B repurchase in the quarter; share count down
- Company executed $1B of opportunistic share repurchases in Q3.
- Diluted share count: 193.9M (-0.7% YoY) reflecting buybacks.
- This also influenced below-the-line items: net interest expense guidance slightly up (lower interest income after repurchases).
- No dividend mentioned; emphasis is on buybacks.
Exclusive for Stockcircle Pro members
Sign up
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $63.35 Billion |
|---|---|
| Enterprise Value | $72.65 Billion |
| Dividend yield | 0.73% |
| Earnings per Share | $8.02 |
| Beta | 0.56 |
| Outstanding Shares | 193,147,000 |
Return
| Return on Equity | 86.03% |
|---|---|
| Return on Assets | 3.13% |
| Return on Invested Capital | 10.93% |
Valuation & Multiples
| P/E Ratio | 24.47 |
|---|---|
| PEG | 220.99 |
| Price to Sales | 0.1 |
| Price to Book Ratio | 11.25 |
| Enterprise Value to Revenue | 0.22 |
| Enterprise Value to EBIT | 27.02 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 3.97 |
Revenue Sources
No data
Last Earnings Call
Report Date
February 4, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.52, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.5241▼ 38.87% |
|---|---|
| Total Calls | 2,499,247▼ 45.15% |
| Total Puts | 1,309,747▼ 68.51% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 91.57%▼ 3.60% |
|---|---|
| Total Invested | $33.23B▼ 3.78% |
| Investors Holding | 1,358▼ 40.00% |
About Amerisource Bergen Corp.
22,000 employees
CEO: Steven Collis
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their part...